Objective: The prevalence of type 2 diabetes is increased in polycystic ovary syndrome (PCOS), but the prevalence of other diseases is not clarified. We aimed to investigate morbidity and medicine prescriptions in PCOS. Design: A National Register-based study. Methods: Patients with PCOS (PCOS Denmark and an embedded cohort; PCOS Odense University Hospital (OUH)) and one control population. Premenopausal women with PCOS underwent clinical and biochemical examination (PCOS OUH, nZ1217). PCOS Denmark (nZ19 199) included women with PCOS in the Danish National Patient Register. Three age-matched controls were included per patient (nZ57 483). Main outcome measures: Diagnosis codes and filled prescriptions. Results: The mean (range) age of the PCOS Denmark group and controls was 30.6 (12-60) years. Patients in PCOS Denmark had higher Charlson index, higher prevalence of diabetes, dyslipidemia, and hypertension than controls. PCOS was associated with a two times increased risk of stroke and thrombosis, whereas the risk of other cardiovascular diseases was not increased. Thyroid disease, asthma, migraine, and depression were more prevalent in PCOS Denmark vs controls, whereas fractures were rarer. Infertility was increased in patients compared with controls, but the mean number of births was higher in PCOS. Medicine prescriptions within all diagnosis areas were significantly higher in PCOS patients than in controls. In PCOS OUH, polycystic ovaries (PCO) and irregular menses were associated with a more adverse metabolic risk profile, but individual Rotterdam criteria were not associated with cardiometabolic diagnoses. Conclusion: Cardiometabolic and psychiatric morbidity were significantly increased in a Danish population with PCOS. Medical diseases are frequent also in young patients with PCOS.
Introduction increased risk of diabetes and thus increased number of cardiovascular risk factors (7, 8, 9) . Retrospective studies reported significantly higher frequency of hypertension and cardiovascular disease in PCOS, especially in women with irregular cycles (10, 11, 12, 13) . Recommendations for the diagnosis and follow-up of patients with PCOS include screening for the metabolic syndrome and other cardiovascular risk factors with regular intervals (3, 14) . These recommendations are based on clinical studies, whereas no register-based studies evaluated the prevalence of diabetes and cardiovascular disease in patients diagnosed with PCOS.
Hyper-inflammation in PCOS could affect the autoimmune function (15) and in small clinical studies the prevalence of autoimmune thyroiditis was increased (16) . Furthermore, respiratory function in patients with asthma was associated with menstrual pattern (17) and PCOS could therefore be associated with changed respiratory health (17) . These hypotheses could be further tested by studying the prevalence of thyroid and asthma diagnoses in populations with PCOS along with the medicine prescription pattern of thyroid hormones, anti-thyroid medicine, and asthma medicine.
Quality of life is impaired in patients with PCOS and the risk of depression is approximately eight times increased compared with controls (18, 19) . PCOS could therefore be associated with increased use of antidepressants, analgesics, and neuropsychiatric medicine, but few studies evaluated this hypothesis. We recently reported that 20% of reproductive-aged patients with PCOS from our uptake area had prescriptions of antidepressants during follow-up compared with 15% healthy controls (20) . However, to our knowledge, no population-based study investigated the prevalence of psychiatric and neurological diagnoses in patients with PCOS.
The aim of the present register-based study was to investigate possible associations between the diagnosis of PCOS and morbidity evaluated by diagnosis codes in the Danish National Patient Register (NPR) and medical prescriptions from the National Prescriptions Registry. Possible associations between individual Rotterdam criteria and cardiometabolic health were investigated in a well-described subgroup of patients with hyperandrogenism and/or PCOS.
Patients and methods
The study was designed as a register-based study including two patient populations with PCOS and a control population.
Population 1, PCOS Odense University Hospital
This embedded cohort included premenopausal women referred to the outpatient clinic at the Department of Endocrinology and Metabolism, Odense University Hospital (OUH) during 1997-2012 with the diagnoses of hirsutism (L680) and/or PCOS (E282).
Inclusion criteria
Women were included if they fulfilled the Rotterdam criteria for PCOS or had clinical and/or biochemical hyperandrogenism (21, 22, 23) .
Exclusion criteria
Women younger than 15 years were referred to the Department of Pediatrics at Odense University Hospital and patients with a primary complaint of infertility were referred to the local Fertility Clinic. Patients with serious endocrine diseases were excluded as previously described (8) . Patients not attending for the measurement of hormonal or metabolic parameters were excluded.
Three patients diagnosed with PCOS before the age of 15 were included in the study as they underwent full evaluation at our department after the age of 15 years. Patients paused oral contraceptives for at least 3 months before evaluation.
Methods
Routine evaluation included medical history, clinical examination, transvaginal ultrasound, and fasting blood samples (8) . Patients with regular periods and cycle length of 27-35 days were classified as having regular menses. The remaining patients were classified as anovulatory. Hirsutism was assessed by the Ferriman Gallwey score (FG-score) (24) . Waist circumference was measured to the nearest centimeter in a standing position midway between the lower costal margin and the iliac crest.
Fasting blood samples were drawn in follicular phase (cycle days 2-8) in patients with a cycle length shorter than 3 months, while patients with cycle length O3 months had the blood samples drawn on a random cycle day. Blood tests included androgens (total testosterone, freetestosterone, sex hormone-binding globulin (SHBG), dehydroepiandrostenedione sulfate, 17-hydroxyprogesterone), LH, FSH, prolactin, HbA1c, lipid profile insulin, and blood glucose.
Assays
Serum total testosterone and SHBG were analyzed using a specific RIA after extraction as previously described (25) . The method has a close correlation with the determination of testosterone levels by mass spectrometry. The intra-assay coefficient of variation (CV) for total testosterone was 8.2 and 5.2% for SHBG. The inter-assay CV for total testosterone was 13.8 and 7.5% for SHBG. Free testosterone levels were calculated from measurements of total testosterone and SHBG. Insulin was analyzed by a time-resolved fluoroimmunoassay using a commercial kit (AutoDelfia, Wallac Oy, Turku, Finland) with an intraassay variation 2.1-3.7% and inter-assay variation 3.4-4.0%. Reference intervals for the individual hormones were as follows: total testosterone 0.55-1.8 nmol/l, free testosterone 0.006-0.034 nmol/l, SHBG 41-170 nmol/l, and insulin 18-173 pmol/l.
Plasma total cholesterol, HDL cholesterol, and triglycerides (TG) were analyzed by enzymatic colorimetric reactions (Modular P, Roche), while LDL cholesterol was calculated using the Friedewald equation. Blood glucose was measured on capillary ear blood using Hemo Cue. We calculated HOMA-RZfasting insulin!fasting blood glucose/22.5 (26) , reference %15 pmol mmol l K2 . (27) . The current sub-classification of diabetes mellitus types was not used until 1994, as the ICD8 coding classified diabetes mellitus patients as having insulindependent diabetes mellitus (ICD8 code 249) or noninsulin-dependent diabetes mellitus (ICD8 code 250). Hence, the GDM diagnosis did not exist in the ICD8 coding and a decision was made to include data from 1994 and onwards in this study. PCOS can only be diagnosed after menarche (28) and therefore only patients aged 12 years or more were included in the PCOS Denmark study population (29) . The index year was defined as the first time a patient received the diagnosis L680 or E282. The PCOS OUH population was a subset of the PCOS Denmark population.
Population 2, PCOS Denmark

Controls
For each patient in the PCOS Denmark population three controls were randomly drawn from the NPR. The controls were born in the same year as PCOS cases and had to be alive on the index date of their respective PCOS case. Controls were assigned the index date of their matched PCOS cases.
Exclusion diagnoses
The PCOS diagnosis requires exclusion of diagnoses that may cause symptoms similar to the condition (1). We excluded subjects in both study arms with a history of the following conditions: E221 (hyperprolactinemia), E220 (acromegaly), E24 (Cushing's disease), E25 (adrenogenital syndrome), and Q96 (Turner syndrome).
The Danish Health Registries
All individuals in Denmark are assigned with a unique personal identification number and data from all public registers can be linked at an individual level. All ICD10 hospital diagnoses were extracted from the NPR on the total study population. Information on all prescriptions issued by prescribers, general practitioners, or specialists in Denmark from 1995 to 2012 were retrieved from the National Prescriptions Registry. The National Prescriptions Registry database contains a complete record of Anatomic Therapeutic Chemical code, date drug dispensed, number of drug packets, and number of tablets per packet for all prescriptions filled at Danish pharmacies. The National Cause of Death Register contains information on all deaths. It includes death certificate diagnoses and date of death. The core study was an open register-based cohort study. The present paper is a description of baseline characteristics preceding the first diagnosis of PCOS (the index date). Specifically, for comorbid conditions, we included hospital contacts since 1995. The Charlson Comorbidity Index is based on 19 comorbid conditions (30) and was calculated from the ICD10 operationalization by Quan et al. (31) . For prescriptions, we made a distinction between recent use (at least one prescription of the drug in question in the last 12 months before the index date) and ever use (at least one prescription since establishment of the register in 1995 to the index date). The study did not need approval from the local Ethics committee or Institutional Review Board by Danish law. Transfer of patient data from the PCOS OUH cohort to Statistics Denmark (project no 704175) for merging with national datasets was approved by the Data Protection Agency.
Statistical analyses
The statistical approach addressed two main questions: i) did the patients in PCOS OUH differ from patients in PCOS Denmark on key characteristics and ii) did the patients in PCOS Denmark differ from random population controls. Descriptive analyses for categorical variables (e.g., diabetes, thyroid disease) were presented as frequencies and evaluated by c 2 tests. Continuous variables (e.g., number of births) were tabulated as medians (with quartiles) or means (with S.D.) depending on their distribution. Mann-Whitney U tests were used to test for differences between the groups for these variables. P values below 0.05 were considered to be statistically significant. All analyses were conducted using STATA 13 through a remote VPN access to Statistics Denmark and the analysts were blinded to the personal identities of the study subjects.
Results
The flow chart of included women is summarized in Fig. 1 .
PCOS OUH (nZ1217): clinical, biochemical data, and individual Rotterdam criteria
Clinical and biochemical data from the PCOS OUH cohort are presented in Table 1 . Patients with PCO (nZ1085) were younger and had higher BMI, waist, T-testosterone, fasting BG, fasting insulin, and HOMA-R levels compared with patients with normal US, whereas FG-score was lower ( Table 2 ).
The majority of patients had biochemical and/or clinical hyperandrogenism (1124/1211Z92.8%, Table 2 ). Measures of body composition and metabolic risk profile were comparable in patients with and without hyperandrogenism.
Patients with irregular menses were younger and had higher BMI, waist, total-and free testosterone, TG, fasting BG, fasting insulin, and HOMA-R levels compared with patients with regular menses, whereas FG-score, SHBG, and HDL were lower (Table 2 ).
Characteristics and diagnoses in patients with PCOS and controls (nZ76 682)
PCOS Denmark (nZ19 199) vs controls (nZ57 483) " The mean age of the PCOS Denmark group and controls were 30.6 years. The Charlson Index was higher in patients with PCOS compared with controls. The PCOS Denmark group had higher prevalence of the diagnoses obesity, all types of diabetes, dyslipidemia, hypertension, stroke, and thrombosis compared with controls, whereas the risk of cardiovascular disease, myocardial infarction, and transitory cerebral ischemia was not increased in PCOS. Furthermore, patients with PCOS had increased prevalence of all types of thyroid disease, asthma, depression, migraine, cholecystitis, and malignant diseases compared with controls, whereas fractures were found in fewer patients. The prevalence of infertility was higher in PCOS compared with controls, but the mean number of births was higher in PCOS and the distribution of number of births differed significantly between patients and controls. Exclusion (E221, E220, E24, E25, and Q96) n =376
Exclusion (death before indexdate) n =1
Women aged 12-60 with L680 or E282 from NPR n =19 576
PCOS Controls
Matched controls by year of birth, 1:3 n =57 597 Exclusion (E221, E220, E24, E25, and Q96) n =88
Exclusion (death before indexdate) n =26
Total population included in the study n =76 682
Including OUH PCOS as a subset of NPR PCOS group n =1 217 n =57 483 n =57 509 n =19 199
Figure 1
Flowchart of included subjects. (Table 3) . Patients in the PCOS OUH group had lower prevalence of migraine, malignant disease and infertility compared with the PCOS Denmark group. Otherwise, the prevalence of diagnoses was comparable. Patients in PCOS OUH had lower mean number of births compared with PCOS Denmark and the distribution of number of births differed between the two patient groups.
Medical treatment in patients with PCOS and controls (nZ76 682) " Table 4 gives all time use of medical treatment in the study population.
PCOS Denmark (nZ19 199) vs controls (nZ57 483) " Patients with PCOS had higher use of all types of antidiabetic treatment, anti-lipids, antihypertensives, allergy medicine, asthma medicine, antidepressants, neuroleptics, anxiety medicine, analgesics, thyroid, anti-thyroid treatment, antibiotic treatment, all types of oral contraceptives, gestagen, intrauterine devices, antiandrogen treatment, and fertility treatment compared with controls.
PCOS
OUH (nZ1217) vs PCOS Denmark (nZ19 199) " The prescription of metformin, drospirenone/ethinylestradiol, and fertility treatment was lower in PCOS OUH vs PCOS Denmark, whereas prescriptions of antibiotic treatment and cyproterone acetate/ethinylestradiol were higher. Table 5 gives use of medical treatment 1 year before the diagnosis of PCOS.
PCOS Denmark (nZ19 199) vs controls (nZ57 483) " Patients with PCOS had higher use of metformin, insulin, other anti-diabetics, anti-lipids, antihypertensives, allergy medicine, asthma medicine, antidepressants, neuroleptics, anxiety medicine, analgesics, thyroid and anti-thyroid treatment, antibiotic treatment, oral contraceptives, 3rd generation oral contraceptives, drospirenone/ ethinylestradiol, cyproterone acetate/ethinylestradiol, gestagen, intrauterine devices, spironolactone, vaniqa, and fertility treatment compared with controls. Prescriptions of smoke stop, 2nd generation oral contraceptives, and finasteride were comparable between patients and controls.
PCOS OUH (nZ1217) vs PCOS Denmark (nZ19 199) " Prescriptions for metformin, other anti-diabetics, Table 2 The PCOS OUH patient cohort (nZ1217) and presence of individual Rotterdam criteria. Data presented as median (quartiles) or n (%). In some patients data on ultrasound, hyperandrogenism, or menstrual history were not available. antihypertensives, gestagen, and fertility treatment were lower in PCOS OUH than in PCOS Denmark, whereas prescriptions of intrauterine devices were higher.
Rotterdam criteria in the PCOS OUH population and cardiometabolic diagnoses
The presence of PCO, hyperandrogenism, or irregular menses was associated with obesity (Table 6 ). Six women in the study population had a diagnosis of thrombosis. The prevalence of thrombosis was significantly lower in patients with hyperandrogenism (4/1124Z0.4%) compared with patients without hyperandrogenism (2/87Z2.3%). Five of six patients diagnosed with thrombosis had been treated with oral contraceptives (3rd generation nZ4, drospirenone/ethinylestradiol nZ1).
Discussion
To our knowledge, this is the first nationwide, populationbased study that reports increased morbidity in patients with PCOS compared with healthy age-matched controls. We evaluated morbidity by diagnosis codes and medicine prescriptions before the PCOS diagnosis. The Charlson Index was significantly higher in patients with PCOS than in controls, which support an overall increased morbidity in PCOS. Increased morbidity in PCOS included cardiometabolic as well as autoimmune and psychiatric diagnoses. The mean age of the included study population was 30 years and our data support that medical diseases are prevalent also in young individuals diagnosed with PCOS. In a representative subgroup of patients with PCOS from our outpatient clinic, the presence of individual Rotterdam criteria was associated with obesity, but otherwise we found no association between the presence of individual Rotterdam criteria and cardiometabolic diagnoses. Many different medical conditions have been associated with the diagnosis of PCOS (32) . The risk of type 2 diabetes is currently estimated to be five to ten times increased in PCOS, whereas the risk of cardiovascular disease is debated (3, 9, 13, 33, 34) . The risk of cardiometabolic disease may be highly influenced by BMI, ethnicity, and the presence of different Rotterdam criteria, especially hyperandrogenism (5, 35), whereas high SHBG was a protective factor (34) . In our cohort, 1.5% patients were diagnosed with type 2 diabetes compared with 0.4% controls, which confirmed a five times increased risk of type 2 diabetes in PCOS. Given the register-based design, BMI data were not available in the PCOS Denmark group. The median BMI in PCOS OUH was 27.3 kg/m 2 and the relative risk of diabetes may be even higher in more obese study populations. Our findings of three times increased risk of dyslipidemia and hypertension in the PCOS Denmark cohort vs controls support clustering of cardiovascular risk factors in PCOS. Furthermore, the prescription of anti-lipids and antihypertensives was two times higher in patients with PCOS vs controls. Antidiabetic medicine including metformin is used to 
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Clinical Study D Glintborg and others Morbidity in polycystic ovary syndrome 172:5treat irregular menses, the metabolic syndrome, and infertility in PCOS, which could explain that the use of antidiabetics was up to 30 times increased in PCOS compared with controls. PCOS was associated with a two times increased risk of stroke and thrombosis, whereas the risk of other cardiac diseases was not increased. The presence of individual Rotterdam criteria was not associated with cardiometabolic outcome despite a more adverse metabolic risk profile in patients with PCO and irregular menses. It is possible that the inclusion of a young, relatively lean study population affected our results and further prospective studies are needed to determine whether the long-term metabolic risk is affected by PCOS phenotype. The number of cases diagnosed with thrombosis in PCOS OUH was limited and more data are needed on risk factors for thrombosis in patients with PCOS. Oral contraceptives are often used to treat hyperandrogenism and irregular menses in PCOS and five of six patients with thrombosis had been treated with oral contraceptives. Accordingly, the risk of venous thromboembolism was reported to be 1.5-fold increased among women with PCOS not taking oral contraceptives and twofold increased among women with PCOS who were taking combined oral contraceptives (36) . Furthermore, the risk of thrombosis may be affected, which generation of oral contraceptive was used as 4th generation oral contraceptives containing drospirinone had the highest thromboembolic risk (37) .
The overall presence of thyroid diseases was 3.6 times increased in PCOS vs controls. Correspondingly, prescriptions of thyroid medicine were three times increased in PCOS. These data are in agreement with clinical studies reporting that thyroid autoantibodies and autoimmune thyroiditis were more prevalent in patients with PCOS compared with controls (16, 38) . These findings lead to a hypothesis of altered immune function in PCOS, which could be mediated by increased inflammatory status, unbalanced estrogen/progesterone secretion, or still unknown mechanisms (16) . Similar mechanisms were suggested to affect respiratory health and to increase the risk of asthma in women with irregular menses (17) . Our findings of significantly increased risk of asthma, however modest, underline the need for studies in patients with PCOS. Furthermore, the levels of various auto-antibodies were higher in PCOS vs controls (15) and the risk of rheumatologic or other autoimmune diseases may also be increased in PCOS (15) .
Depression was 2.8 times more common in patients with PCOS vs controls and 1.9 times more patients than controls had prescriptions of antidepressants. The discrepancy between 1.4% patients diagnosed with depression and 16.3% patients treated with antidepressants could be explained by the fact that many patients are treated for depression by their own general practitioner and only hospital diagnoses are included in NPR. The present data support a moderately increased risk of depression in PCOS and are in agreement with recent studies (2, 20, 39) . In contrast, some studies reported an up to eightfold increased risk of depression in PCOS (18) , but treatment with antidepressants is only indicated in moderate or severe and psychotherapy should be used in patients with milder symptoms. Based on the present data, we cannot conclude whether patients with PCOS are medically undertreated or have milder depression symptoms without need for medical treatment.
We found that the use of anxiety medicine was higher in patients with PCOS compared with controls. These results are supported by a recent register-based Taiwanese study reporting a hazard ratio of 1.4 for anxiety disorders in PCOS (39) . Anxiety could be associated with depression and low quality of life in PCOS, but more studies are needed to test this hypothesis.
A novel finding of the present study was a two times higher risk of migraine/headache in PCOS vs controls and correspondingly a 1.7 times higher prescription rate of analgesic and migraine medicine. We are not aware of similar findings in previous studies and these results need to be reproduced in other cohorts of patients with PCOS. Testosterone treatment improved symptoms of migraine in pre-and postmenopausal women (40) , whereas decreased dihydrotestosterone levels during treatment with finasteride improved migraine symptoms (41) . Furthermore, increased use of analgesic medicine could be associated with the use of oral contraceptives, decreased quality of life in PCOS, or the presence of somatic diseases. The evaluation of the use of analgesic medicine is complicated by the fact that paracetamol and low dose NSAID can be bought over the counter in Denmark.
The prevalence of prior fractures was significantly lower in PCOS vs controls and support previous findings of normal or higher bone mineral density in PCOS and hirsute patients compared with controls (42). We did not Oral contraceptive treatment is the most widely applied treatment modality in PCOS (49) . Oral contraceptives regulate menstrual cycles and SHBG levels increase, leading to decreased levels of free testosterone and decreased hirsutism scores (49) . A nearly double prescription rate of oral contraceptives in PCOS was therefore not surprising. Furthermore, increased use of cycle regulating medicine, IUD, and antiandrogen treatment was expected in patients with PCOS. Fertility and pregnancy outcome was not the primary outcome of this study. Our data supported that the number of births was not reduced in patients with PCOS despite a significantly higher rate of diagnosed infertility and increased prescription of fertility treatment in PCOS. The inclusion of a relatively lean study population could explain some of our results as the number of births were reduced in obese study populations with PCOS (50) . The observed fewer diagnoses of infertility and different distribution of number of births in PCOS OUH compared with PCOS Denmark may be explained by the exclusion of women with fertility plans from PCOS OUH.
The strength of this study is the inclusion of a large and well-characterized group of patients with PCOS, the ability to embed a clinical cohort into a national registerbased study, and the access to well validated register-based data with a long record of past drug exposures. Some limitations may however apply to this study design. No data were available on patients not attending the outpatient clinic. Patients not attending the clinic could differ from included patients. Many patients with PCOS are not seen at the hospital, but are treated by their general practitioner or a private gynecologist. Therefore, some women in the control group will have undiagnosed PCOS, which will lead to underestimation of morbidity and medicine use in PCOS. This study was not a cross sectional study on the prevalence of PCOS, but included patients diagnosed over a number of years. Therefore, there may be an influence of temporal trends in obesity and in the diagnostic effort and treatment patterns for other conditions, both in the PCOS patients and in control subjects. Patients with isolated hirsutism were included in both PCOS populations as the majority of patients with clinical and/or biochemical hyperandrogenism are diagnosed with PCOS and hyperandrogenism may be closely linked to metabolic disturbances in PCOS (21, 22, 23) . Patients were included from 1994 and onwards, whereas the Rotterdam criteria were introduced in 2003 (1). Especially, the criteria for PCO varied before 2003 and different criteria for PCOS may have been used by endocrinologists and gynecologists (1, 51) . Furthermore, the definition of PCOS in adolescents is debated (52) . The register-based design did not allow us to test the hypothesis that different definitions of PCOS affected study outcomes. We excluded patients and controls with a history of relevant endocrine conditions (1); however, the findings of the present study need to be confirmed in other study populations. Our cohort (PCOS OUH) differed from PCOS Denmark in terms of age, comorbidity, and prescription history. However, these differences were small and therefore unlikely to be a major source of bias in our findings. It is important to be aware that national registers, from which the PCOS Denmark cohort was drawn, do not contain information on BMI or on serum biochemistry. Hence, we are unable to determine if the higher prevalence of cardiometabolic disorders found in the PCOS cohort can be attributed to higher BMI alone or not. This does not detract from the finding that PCOS patients should be carefully screened for these diseases. Further, we were able to demonstrate that the PCOS Denmark cohort, though selected by ICD10 diagnosis codes alone, is reassuringly similar on key characteristics to our carefully clinically and biochemically evaluated PCOS OUH cohort. This is an important step forward as the validity of ICD10 coding for hirsutism in Denmark was previously not known.
In conclusion, morbidity and medicine use was significantly increased in a Danish population with PCOS. Our data confirm that medical diseases are often occurring also in young patients with PCOS. In this study, we found no association between the presence of individual Rotterdam criteria and cardiometabolic diagnoses in a well characterized group of patients with PCOS.
